Rekom Biotech, as specialised company in the design and development of biomarkers for infectious diseases, presents a new line of recombinant products, Bioallergens. Our recombinant allergens are biomarkers of non-infectious origin intended for the diagnosis of type I allergic disorders. We open our catalogue with recombinant allergens for pollens and epithelia, that we wish to complete with further categories in order to meet the demands of the allergy testing in the in vitro diagnostic industry.
A wide variety of protein antigens from our environment are proteins coming from food, dust mites, pollens from trees and grasses; and other natural products. These environmental proteins come primarily from non-pathogenic eukaryotic organisms (animals and plants) and are essentially innocuous. However, in some cases, our immune system reacts to them, unintentionally causing damage to our tissues and vital organs that occasionally generates serious systemic pathologies.
The development of recombinant allergens provides new opportunities for the improvement of the diagnosis of immunoglobulin E (IgE) mediated allergies, given that they present capacity for binding these antibodies in a comparable way to natural allergens and generally show good reactivity in in vitro diagnostic test. For this reason, recombinant allergens are of a great interest to both the research field and the development of new diagnostic test for IgE quantification in the clinical routine.
The recombinant allergens developed by Rekom Biotech have been evaluated in an external study carried out at a Spanish hospital by a group of allergists with positive and negative serum samples from patients. In this study, it has been determined the presence of specific IgE in sera that had previously been validated by skin prick testing (SPT) and the UniCAP® test.
For the completion of this evaluation, an ELISA immunoassay was developed at the hospital that allowed the quantification of specific IgE in the patient sera and the collection of incidence data for each biomarker in the analysed population. This incidence was subsequently compared to the data described by bibliography, finding a complete correlation.
The measure of circulating IgE antibodies specific for a determined allergen provides information about the patient sensitisation to this allergen. In general, low IgE levels would indicate a low probability of developing a clinical disease, while high IgE levels would show a high correlation of developing disease.
Through an adequate diagnostic test incorporating our biomarkers, it would be possible to determine the allergen to which the patient is reacting and the levels of specific IgE to this allergen. This quantification will allow to predict more accurately the chance of the patient developing a disease, and thus the need for appropriate treatment.
For more information, please visit Rekom Biotech's website at www.rekombiotech.com.